A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer
Breast Cancer, Neoplasm Metastasis
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring metastatic breast cancer, drug therapy, doxorubicin, docetaxel
Eligibility Criteria
Inclusion Criteria: Hormonal therapy-resistant MBC ER (-), failure of hormonal therapy for MBC, or relapse within 6 months after adjuvant hormonal therapy No anthracyclines for MBC and no prior taxanes At least 6 months from the completion of adjuvant chemotherapy Measurable or evaluable lesions Age: 20 to 75 years PS: 0-3 WBC >= 4,000 /mm3 or ANC >=1,000 /mm3, Platelet >= 100,000 /mm3, SGOT/SGPT <= 1.5 x ULN, T-Bil <= 1.5 mg/dL, Cr <= 1.5 mg/dL normal ECG Written informed consent Exclusion Criteria: pregnant malignant pleural effusion, ascites, or pericardial effusion that requires emergent treatment Active infection other cancer present within the last 5 years previous stem cell transplantation brain metastasis that requires emergent treatment relapse within 6 months after completion anthracycline or during anthracycline more than 250mg/m2 of anthracyclines hypersensitivity of drug interstitial pneumonitis or pulmonary fibrosis positive HBs antipsychotic medication doctor's judgement
Sites / Locations
- National Cancer Center Hospital